YUEXIN LIU

Dr. YUEXIN LIU

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2025 in BMJ Open
Verified
Journal Article
Open access
PDF file
HCHui Chang
Hui Chang
XYXingyao Yan
Xingyao Yan
QZQingyao Zhong
Qingyao Zhong
PNPeng Ning
Peng Ning
MWMeilin Weng
Meilin Weng
YLYUEXIN LIU
YUEXIN LIU
Objectives To estimate the burden, trends, and inequalities of brain and central nervous system cancer (CNS cancer) among adults at global, regional and national level from 1992 to 2021. Design Population-based study. Population Adults aged 20–64 years from 21 regions and 204 countries and territories (Global Burden of Disease and Risk Factors Study 2021) from 1992 to 2021. Main outcome measures Our primary outcomes comprised age-standardised prevalence, incidence, mortality and disability-adjusted life-years (DALYs) for CNS cancers. The analytical framework incorporated temporal trend analysis through annual percentage change (APC) and average APC (AAPC) metrics, complemented by Bayesian age-period-cohort modelling to assess demographic influences. We employed predictive modelling with decomposition techniques to evaluate contributions from age structure shifts, population dynamics and risk factor modifications, while spatiotemporal Gaussian process regression enabled robust smoothing and trend estimation across continuous time-space dimensions. The study specifically applied frontier analysis methodologies to examine epidemiological patterns of prevalence, incidence, mortality and DALYs within the 20–64 years adult population. Results From 1992 to 2021, the global age-standardised prevalence (AAPC 1.04 (95% CI 0.91 to 1.18); p<0.001) and incidence (AAPC 0.23 (95% CI 0.14 to 0.31); p<0.001) of CNS cancer among adults aged 20–64 years increased, while age-standardised DALYs (AAPC −0.28 (95% CI −0.34 to −0.22); p<0.001) and mortality (AAPC −0.27 (95% CI −0.34 to −0.2); p<0.001) decreased. The most significant increase in prevalence (AAPC 1.67 (95% CI 1.47 to 1.87); p<0.001) and incidence (AAPC 0.7 (95% CI 0.61 to 0.79); p<0.001) was observed among those aged 20–24 years. The most significant decrease in DALYs (AAPC −0.45 (95% CI −0.55 to −0.35); p<0.001) and mortality (AAPC −0.46 (95% CI −0.56 to −0.36); p<0.001) was observed among those aged 40–44 years. The rate of increase in prevalence and incidence was lower in high sociodemographic index (SDI) (prevalence: AAPC 0.95 (95% CI 0.8 to 1.11); p<0.001), (incidence: AAPC 0.95 (95% CI 0.8 to 1.11); p<0.001) countries compared with low-SDI countries (prevalence: AAPC 0.5 (95% CI 0.43 to 0.57); p<0.001), (incidence: AAPC 0.12 (95% CI −0.07 to 0.31); p<0.001). DALYs and mortality began to decline in high-SDI countries (DALYs: AAPC −0.52 (95% CI −0.73 to −0.31); p<0.001), (mortality: AAPC −0.5 (95% CI −0.7 to −0.3); p<0.001), but these indicators continue to rise in low-SDI nations (DALYs: AAPC 0.45 (95% CI 0.39 to 0.51); p<0.001), (mortality: AAPC 0.38 (95% CI 0.31 to 0.46); p<0.001). Our predictive analysis found that from 2021 to 2050, the number of CNS cancer cases among people aged 20–64 years will be on the rise globally, which is expected to increase from 186 891 to 245 942, an increase of 31.6%. From 1992 to 2021, the global age-standardised prevalence and incidence of CNS cancer among adults aged 20–64 years increased, while age-standardised DALYs and mortality decreased. The most significant increase in prevalence and incidence was observed among those aged 20–24 years. The most significant decrease in DALYs and mortality was observed among those aged 40–44 years. The rate of increase in prevalence and incidence was lower in high SDI countries compared with low-SDI countries. DALYs and mortality began to decline in high-SDI countries, but these indicators continue to rise in low-SDI nations. Our predictive analysis found that from 2021 to 2050, the number of CNS cancer cases among people aged 20–64 years will be on the rise globally, which is expected to increase from 186 891 to 245 942, an increase of 31.6%. Conclusions Significant inequalities exist in age-standardised prevalence, incidence, DALYs and mortality of CNS cancer among countries with varying sociodemographic indices. These disparities highlight the urgent need for targeted clinical guidelines and equitable distribution of global health resources.

30 December 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PCPeng Chen
Peng Chen
JHJiang-Jian Hu
Jiang-Jian Hu
YLYUEXIN LIU
YUEXIN LIU
BCBoxu Cao
Boxu Cao
XSXue-Jun Song
Xue-Jun Song
Ubiquitin-proteasomal degradation of K + /Cl − cotransporter 2 (KCC2) in the ventral posteromedial nucleus (VPM) has been demonstrated to serve as a common mechanism by which the brain emerges from anesthesia and regains consciousness. Ubiquitin-proteasomal degradation of KCC2 during anesthesia is driven by E3 ligase Fbxl4. However, the mechanism by which ubiquitinated KCC2 is targeted to the proteasome has not been elucidated. We report in cultured neuro-2a cells that the valosin-containing protein (VCP) transported ubiquitinated KCC2 to the proteasome and in mice in vivo experiments that inhibition of VCP restored KCC2 expression in the VPM and enhanced the effects of anesthesia. In cultured neuro-2a cells, propofol-induced degradation of KCC2 was inhibited by VCP inhibitor DBeQ and VCP knockout plasmid sgRNA(VCP). Propofol-induced enhanced interaction between VCP and KCC2 was inhibited by knockout of Fbxl4 or Fas-associated factor 1 (FAF1). In in vivo studies, pharmacological or genetic inhibition of VCP in the VPM significantly prevented KCC2 degradation and enhanced propofol anesthesia; these effects were abrogated by a KCC2 antagonist VU0463271. These results demonstrate that the VCP controls ubiquitin-proteasomal degradation of KCC2 dependent on FAF1 recruitment and serves as a mechanism for the ubiquitin-proteasomal degradation of KCC2, which is responsible for the subsequent emergence from anesthesia.

5 December 2025 in Science Advances
Verified
Journal Article
Open access
YLYUEXIN LIU
YUEXIN LIU
JHJiang-Jian Hu
Jiang-Jian Hu
BCBoxu Cao
Boxu Cao
PCPeng Chen
Peng Chen
BPBo Peng
Bo Peng
XSXue-Jun Song
Xue-Jun Song
Understanding the brain’s intrinsic mechanisms that drive the emergence of consciousness from anesthesia remains a substantial and unresolved challenge in brain research. Here, we show in mice that, when the brain is forced into a minimal responsive state by an anesthetic, a rapid activation of EphB1 receptor occurs in the ventral posteromedial nucleus (VPM) of the thalamus and contributes to promote the emergence of consciousness by activating the VPM glutamatergic neuron (VPM Glu ) → primary somatosensory cortex glutamatergic neuron pathway. The ephrinB-EphB1 receptor signaling excites VPM Glu neurons through phosphorylation of NR2B, a subunit of N-methyl-D-aspartate receptors (NMDARs), at tyrosine-1472 (Y1472) and disinhibits VPM Glu neurons through ubiquitin degradation of potassium-chloride co-transporter 2 (KCC2). The EphB1/NR2B Y1472 phosphorylation and EphB1/KCC2 ubiquitin degradation are two independent mechanisms in the process of emergence from anesthesia and occur independent of the molecular targets of anesthesia. The present study provides insights into understanding the molecular and neural circuit basis that allows the brain to emerge from anesthesia and regain consciousness.

15 September 2025 in Frontiers in Molecular Neuroscience
Verified
Journal Article
Open access
PDF file
SLSiJing Liao
SiJing Liao
FZFei-Ran Zhou
Fei-Ran Zhou
QLQun Li
Qun Li
TJTao Jin
Tao Jin
GXGui-Fang Xiang
Gui-Fang Xiang
YZYing Zhang
Ying Zhang
Introduction: Central neuroinflammation is pivotal in neuropathic pain pathogenesis, with blood-spinal cord barrier (BSCB) dysfunction recognized as a trigger for neuroinflammation and pain, though molecular mechanisms remain poorly understood.Methods: Through comparative clinical studies measuring serum endoglin in postherpetic neuralgia (PHN) patients versus healthy controls, and animal investigations using spared nerve injury (SNI) rat models with recombinant endoglin intervention, we assessed mechanical/thermal hyperalgesia, microglial activation, inflammatory cytokines, BSCB permeability, and TGF-βRI/Smad2/NR2B phosphorylation.Results: PHN patients exhibited lower serum endoglin versus controls; SNI rats showed reduced spinal endoglin compared to sham controls. Recombinant endoglin alleviated hyperalgesia while reversing microglial activation, inflammation, BSCB impairment, and NR2B phosphorylation. SNI decreased spinal TGF-βRI expression and Smad2 phosphorylation.Discussion: These findings demonstrate that endoglin reduction disrupts BSCB integrity via TGF-β/Smad2 pathway inhibition in endothelial cells, driving microglial activation, neuroinflammation, and NR2B phosphorylation, thereby elucidating a key pain mechanism and identifying endoglin as a therapeutic target.

29 September 2025 in Frontiers in Molecular Neuroscience
Verified
Journal Article
Open access
PDF file
SLSiJing Liao
SiJing Liao
FZFei-Ran Zhou
Fei-Ran Zhou
QLQun Li
Qun Li
TJTao Jin
Tao Jin
GXGui-Fang Xiang
Gui-Fang Xiang
YZYing Zhang
Ying Zhang
A correction refers to a change to their article that the author wishes to publish after publication. The publication of this article is subject to Frontiers' editorial approval. Instructions: ● Please read through all the templates before choosing ● Pick the most relevant text template(s) from the following page and delete all others. ● Edit the text as necessary, ensuring that the original incorrect text is included for the record, please see the below. ● Please do not use any extra formatting when editing the templates, and only modify the red text unless absolutely necessary ● Submit to Frontiers following the instructions on this page. When the original text contained incorrect information, to preserve the scientific record, please include that text when editing the below templates. For example: There was a mistake in the Funding statement, an incorrect number was used. The correct number is "2015C03Bd051.". The publisher apologizes for this mistake. The original version of this article has been updated. In the published article, there was a mistake in the Funding statement. The funding statement for the Key Development Project of the Department of Science and Technology was displayed as "2015CBd051". The correct statement is "Key Development Project of Department of Science and Technology (2015C03Bd051).'' Correction: Endoglin alleviates neuropathic pain by protecting the blood–spinal cord barrier through the TGF-β/Smad2 signaling pathway Correction on: Liao S, Zhou F-R, Li Q, Jin T, Xiang G-F, Wang X, Liu Y, Zhu H, Liu Q, Liu Y and Zhang Y (2025) Endoglin alleviates neuropathic pain by protecting the blood–spinal cord barrier through the TGF-β/Smad2 signaling pathway. Front. Mol.Neurosci.18:1603619.doi:10.3389/fnmol.2025.1603619 Author affiliation Affiliation [1、Traditional Chinese Medicine Hospital of Meishan, Meishan, China 2、 The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, China 3、Hejiang Traditional Chinese Medicine Hospital, Luzhou, China] was erroneously given as [1、Traditional Chinese Medicine Hospital of Meishan, Meisham, China 2、Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, China 3、Hejiang County Traditional Chinese Medicine Hospital, Luzhou, China].. The original version of this article has been updated.

30 September 2026 in Advanced Science
Verified
Journal Article
Open access
PDF file
BPBo Peng
Bo Peng
XLXiaqing Lin
Xiaqing Lin
HYHongyu Yao
Hongyu Yao
CLCheng Li
Cheng Li
HLHuabao Liao
Huabao Liao
XSXue-Jun Song
Xue-Jun Song
Opioids are the primary treatment for severe pain in clinical practice. However, repeated exposure to opioids leads to tolerance, and underlying mechanisms remain elusive. The present study demonstrates that EphB1 receptors play an important role in opioid antinociception through orchestrating µ‐opioid receptor (MOR) trafficking. Morphine administration activates EphB1 receptors in the dorsal root ganglion (DRG) and the spinal cord. Deletion of EphB1 receptors in DRG neurons or vesicular glutamate transporter 2 (Vglut2)‐expressing neurons in the spinal dorsal horn (DH) augments morphine antinociception. MOR and EphB1 receptors are co‐expressed in the somata and axons of DRG neurons and DH Vglut2 + neurons. Deletion of EphB1 receptors in DRG neurons increases opioid‐induced suppression of calcium currents, and ablation of EphB1 receptors in Vglut2 + neurons enhances opioid‐induced inhibition of excitatory synaptic transmission and induction of outward currents in Vglut2 + DH neurons. Mechanistically, EphB1 receptors form a complex with MOR and G protein‐coupled receptor kinase 2 (GRK2) and regulate GRK2‐mediated phosphorylation of MOR at Ser 375 , thus controlling MOR internalization. These findings support the idea that activation of EphB1 receptors may facilitate the development of opioid tolerance through regulating MOR.